We are live on ! Find out more
JY

Jeff Yass Susquehanna International Group

AUM $1.28T
1-Year Est. Return 58.89%
 

Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.

This Fund
S&P 500
This Quarter Est. Return
+11.22%
1 Year Est. Return
+58.89%
3 Year Est. Return
+161.44%
5 Year Est. Return
+153.95%
10 Year Est. Return
+545.54%
AUM
$347B
AUM Growth
+$49B
Cap. Flow
+$12.7B
Cap. Flow %
3.67%
Top 10 Hldgs %
25.82%
Holding
11,328
New
1,232
Increased
3,827
Reduced
4,449
Closed
1,709

Top Buys

Rank Stock Value
1
BA icon
Boeing
BA
+$1.33B
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$781M
3
TSLA icon
Tesla
TSLA
+$468M
4
QQQ icon
Invesco QQQ Trust
QQQ
+$467M
5
HD icon
Home Depot
HD
+$344M

Sector Composition

Rank Sector Weight
1 Technology 2.2%
2 Consumer Discretionary 1.94%
3 Communication Services 1.89%
4 Healthcare 1.12%
5 Financials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CIG icon
9176
CEMIG Preferred Shares
CIG
$5.78B
$77K ﹤0.01%
+44,156
New +$72.1K
NHTC icon
9177
PUT
Natural Health Trends
NHTC
$15.1M
$77K ﹤0.01%
14,400
-14,500
-50% -$92.8K
TOO
9178
DELISTED
Teekay Offshore Partners L.P.
TOO
$77K ﹤0.01%
49,938
-83,134
-62% -$128K
ABEV icon
9179
CALL
Ambev
ABEV
$45.2B
$76K ﹤0.01%
16,300
-10,200
-38% -$45.2K
GYRE icon
9180
PUT
Gyre Therapeutics
GYRE
$708M
$76K ﹤0.01%
+1,493
New +$62.6K
ICMB icon
9181
CALL
Investcorp Credit Management BDC
ICMB
$12.2M
$76K ﹤0.01%
+11,379
New +$77.1K
TOUR
9182
Tuniu
TOUR
$52.6M
$76K ﹤0.01%
+3,035
New +$85.2K
TRT
9183
Trio-Tech International
TRT
$104M
$76K ﹤0.01%
38,202
-27,390
-42% -$50K
ACGN
9184
DELISTED
Aceragen Inc
ACGN
$76K ﹤0.01%
2,446
+704
+40% +$26.2K
KDNY
9185
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$76K ﹤0.01%
12,780
+6,381
+100% +$34.7K
LAB icon
9186
PUT
Standard BioTools
LAB
$255M
$75K ﹤0.01%
21,500
-33,100
-61% -$116K
RDHL
9187
PUT
Redhill Biopharma
RDHL
$3.68M
$75K ﹤0.01%
12
-6
-33% -$38.3K
GLMD icon
9188
Galmed Pharmaceuticals
GLMD
$4.49M
$74K ﹤0.01%
9
-1
-10% -$6.87K
RIGL icon
9189
Rigel Pharmaceuticals
RIGL
$873M
$74K ﹤0.01%
3,463
-5,804
-63% -$119K
PVLA
9190
Palvella Therapeutics
PVLA
$2.14B
$74K ﹤0.01%
257
-486
-65% -$135K
RJI
9191
DELISTED
AB Svensk Ekportkredit ELEMENTS Linked to the Rogers International Commodity Index-Total Return
RJI
$74K ﹤0.01%
13,778
-52,126
-79% -$272K
PACB icon
9192
Pacific Biosciences
PACB
$472M
$73K ﹤0.01%
14,187
-91,232
-87% -$464K
PERI icon
9193
Perion Network
PERI
$385M
$73K ﹤0.01%
11,751
-12,112
-51% -$63.9K
VERI icon
9194
CALL
Veritone
VERI
$87.4M
$73K ﹤0.01%
29,500
-34,700
-54% -$100K
TYME
9195
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$73K ﹤0.01%
51,961
-5,364
-9% -$6.51K
CVIA
9196
PUT
DELISTED
Covia Holdings Corporation Common Stock
CVIA
$73K ﹤0.01%
35,800
-22,100
-38% -$35.7K
LITS
9197
Lite Strategy Inc
LITS
$35.7M
$72K ﹤0.01%
1,443
-22,661
-94% -$842K
NAGE
9198
CALL
Niagen Bioscience
NAGE
$259M
$72K ﹤0.01%
16,800
+3,600
+27% +$12.8K
HPR
9199
DELISTED
HighPoint Resources Corporation
HPR
$72K ﹤0.01%
858
-173
-17% -$11.3K
TOO
9200
CALL
DELISTED
Teekay Offshore Partners L.P.
TOO
$72K ﹤0.01%
46,900
-46,000
-50% -$70.7K

Similar funds

Jeff Yass's Q4 2019 Portfolio in Review

As of Q4 2019, Jeff Yass held 11,328 positions worth $347B, up 16% from $298B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Jeff Yass deployed $12.7B of net new capital in Q4 2019, opening 1,232 new positions and adding to 3,827 existing holdings. Its largest new stake was Invesco Zacks Mid-Cap ETF: 1,353,476 shares worth $104M.

By sector, the portfolio is most concentrated in Technology at 2.2% of assets, up from 2.1% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was Amazon, an estimated $1.36B trimmed.

  • Jeff Yass's largest Q4 2019 buy was Invesco Zacks Mid-Cap ETF: 1,353,476 shares worth $104M.
  • Jeff Yass added most to Boeing in Q4 2019, an estimated $1.33B increase.
  • Jeff Yass's biggest Q4 2019 reduction was Amazon, cutting an estimated $1.36B.
  • Jeff Yass fully exited Celgene Corp in Q4 2019, selling an estimated $164M.
  • Jeff Yass's ten largest holdings make up 26% of its $347B portfolio in Q4 2019.
  • Jeff Yass opened 1,232 new positions and closed 1,709 in Q4 2019.
  • Jeff Yass's portfolio value rose 16% quarter-over-quarter to $347B.

Based on Susquehanna International Group's 13F filing for Q4 2019, filed 14 Feb 2020.